Huawei, Nokia and top Japanese brands discussed the licensing conflicts confronting the industry in front of a packed room in Shanghai
IAM is currently seeking nominations for individuals to be considered for the 2020 edition of the Strategy 300 - our unique guide to the men and women who excel in the creation of IP value
Facebook and 3M share their plans to tackle gender disparity in the patent system
IAM’s biggest autumn reads
A guiding light through the lawsuits and legislation that are giving patent professionals plenty to think about
US innovators complain of a system in dire straits, but what does the data tell us?
Beijing-based company is expanding from software to hardware, but video app TikTok’s runaway stateside success has put a target on its back
As China opens up and tariffs bear down, what impact is the US/China trade stand-off having on patents?
The decision means that Indivior’s Sublocade is no longer eligible for lucrative exclusivity, but leaves concerns about evergreening unaddressed
With several leading Democratic candidates threatening to circumvent pharma IP, next year’s election could prove pivotal for right owners
Get your deals done now before the market begins to rebalance in favour of patent owners, Allen Lo advises licensees while speaking on panel at the annual IP Dealmakers conference
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016
But a US federal judge ruled last month that UMC and Fujian Jinhua can review Micron’s evidence against them in the Special Administrative Region
Read our most recent monthly round-up for key pharma and biotech IP stories from October 2019
Artificial intelligence has the potential to change the entire nature of the invention process and, therefore, the criteria under which patents are awarded